Core Insights - Skye Bioscience is collaborating with Arecor Therapeutics to develop a higher concentration formulation of nimacimab, a CB1 inhibitor, utilizing Arecor's Arestat™ technology [1][2][3] - Nimacimab is currently being evaluated in a Phase 2a clinical trial for obesity, with initial data expected in late Q3 or early Q4 2025 [2][5] - The partnership allows Skye to fund Arecor's development activities and potentially license the new formulation and associated intellectual property [2][3] Company Overview - Skye Bioscience focuses on developing next-generation therapeutic pathways for metabolic health, particularly through G-protein coupled receptors [5] - The company is conducting a Phase 2a clinical trial for nimacimab, which is a negative allosteric modulating antibody that inhibits CB1 [5] - Arecor Therapeutics aims to enhance existing therapeutic products and has a proprietary technology platform, Arestat™, supported by a strong patent portfolio [4] Product Development - Nimacimab has a pharmacokinetic profile with a half-life of 18–21 days, which is significantly longer than GLP-1-based therapies, and is being evaluated for once-weekly dosing [3] - The collaboration aims to address issues related to tolerability and adherence seen in approved weight loss drugs, as well as concerns about neuropsychiatric toxicities associated with small molecule CB1 inhibitors [3]

Core Insights - Mangoceuticals, Inc. has secured exclusive licensing and distribution rights for Diabetinol® in the U.S. and Canada, targeting the pre-diabetic and weight loss markets [1][3] - Diabetinol® is a patented plant-based nutraceutical derived from citrus peel, clinically shown to improve insulin sensitivity and metabolic health [2][6] - The product aims to address the growing diabetes crisis, with over 30 million Americans suffering from type 2 diabetes and 97.6 million adults having prediabetes [4][5] Market Opportunity - The addressable market for diabetes and metabolic health solutions is valued at $33.66 billion [3] - U.S. diabetes-related healthcare costs exceed $400 billion annually, while global spending on weight loss and blood sugar-lowering medications is projected to surpass $131 billion by 2028 [5] - There is a significant demand for affordable metabolic health solutions, as many individuals discontinue second-line therapies due to cost or tolerability [5][6] Product Details - Diabetinol® will be available in various consumer-friendly formats, including capsules, beverages, pouches, cookies, and gummies [7] - The product is designed to deliver consistent clinical levels of active ingredients and will be marketed through direct-to-consumer online initiatives and retail outlets [7] Clinical Support - Clinical studies indicate that Diabetinol® can significantly improve health markers in patients with type 2 diabetes or prediabetes, including reductions in Hemoglobin A1c and improvements in cholesterol and blood pressure levels [12] - In a pilot study, Diabetinol® reduced peak postprandial blood glucose by approximately 50 mg/dL, which is clinically meaningful for managing glucose metabolism [11] Strategic Vision - The introduction of Diabetinol® aligns with the company's mission to provide safe and accessible wellness solutions amid a growing public demand for natural health products [10] - The product reflects a shift towards preventive, plant-based solutions in healthcare, as emphasized by health leaders [10]